iPSC-based Kidney Disease Modeling

iPSCs have the ability to recapitulate the molecular basis and pathogenesis of a wide range of diseases. Creative Bioarray is dedicated to helping our clients build kidney disease models based on iPSC technologies to develop effective targeted therapies for kidney diseases. We offer high-quality disease modeling solutions based on our expertise and experience in the field of cell reprogramming.

iPSC for Modeling Kidney Disease

Progressive chronic kidney disease in humans usually requires treatment of patients by dialysis and/or kidney transplantation. An incomplete molecular understanding of the disease pathobiology limits the development of effective targeted therapies for clinical use in these diseases. Next-generation, high-fidelity genomic sequencing technology has increased the detection of variants of unknown significance in known and novel genes in patients with inherited kidney disease. Validation of these variants contributes to the pathology of kidney disease, traditionally used to study gene function in animal models and/or cell culture. Currently, iPSC-derived kidney-like organs are reported to have great potential for studying disease progression in vitro.

Multiple studies have established protocols to induce iPSC differentiation into various kidney cell types. iPSC-derived kidney-like organs contain kidney-like structures including glomerular structures, distal tubular cells, Henle cell rings, proximal tubular cells, and in some protocols collect ductal structures in a highly structured and organized manner. The application of kidney-like organs in the field of disease modeling and to some extent in toxicity assessment provides exciting opportunities to develop and screen new therapies and provide improved treatment options.

Fig 1. iPSC-derived kidney cells show multiple potentials for studying diseases in vitro.Fig.1 iPSC-derived kidney cells show multiple potentials for studying diseases in vitro. (O'Neill, 2013)

Our Solutions

We use cell reprogramming techniques to help our clients generate disease-specific iPSCs to mimic kidney disease to accelerate the development of personalized therapeutic regimens and improve translational relevance to clinical care. Our solutions include, but are not limited to:

  • We have established multiple hPSC lines for modeling renal diseases, including autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive PKD (ARPKD), Alport syndrome, renal cyst and diabetes syndrome (RCAD/MODY5), focal segmental glomerulosclerosis (FSGS), and systemic lupus erythematosus. Our patient-specific models for clients studying kidney disease preserve disease-associated mutations to recapitulate their pathogenic phenotypes.
  • For reliable measurements and valid data extrapolation in disease modeling, we use the same genetic background as a control to compare disease lines. Alternatively, we corrected the genetic characteristics in the diseased iPSC lines by overexpression of affected proteins or drug intervention as an adequate control.


  • Development and screening of new therapies
  • Providing modified treatment regimes
  • High-throughput toxicology screening and drug development
  • Biomarker discovery and development


  • Advanced iPSC technology platforms
  • Detailed experimental guidance
  • Customized one-stop service

With professional scientific staff and advanced reprogramming technology, Creative Bioarray has accumulated extensive experience in kidney disease modeling using iPSC technologies. We are well-positioned to provide efficient services to accelerate our clients' scientific research. If you have needs related to disease modeling, please contact us for solutions.


  1. O'Neill, A.C.; Ricardo, S.D. Human kidney cell reprogramming: applications for disease modeling and personalized medicine. Journal of the American Society of Nephrology. 2013, 24(9): 1347-1356.
For Research Use Only. Not For Clinical Use.